MA26825A1 - Derives de pyrazolo [4,3-d] pyrimidine - Google Patents

Derives de pyrazolo [4,3-d] pyrimidine

Info

Publication number: MA26825A1
Authority: MA; Morocco
Prior art keywords: pyrazolo; pyrimidine derivatives; pyrimidine; derivatives
Prior art date: 1999-10-11

Application number

MA26586A

Other languages

English (en)

Inventor

Edward Bunnage Mark

Michael Devries Keith

James Harris Laurence

Charles Levett Philip

Paul Mathias John

Teresa Negri Joanna

Derek Albert Street Stephen

Shaw Wood Albert

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-11

Filing date

2002-04-05

Publication date

2004-12-20

1999-10-11 Priority claimed from GBGB9924063.2A external-priority patent/GB9924063D0/en

2000-07-28 Priority claimed from GB0018656A external-priority patent/GB0018656D0/en

2002-04-05 Application filed by Pfizer filed Critical Pfizer

2004-12-20 Publication of MA26825A1 publication Critical patent/MA26825A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

MA26586A 1999-10-11 2002-04-05 Derives de pyrazolo [4,3-d] pyrimidine MA26825A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9924063.2A GB9924063D0 (en)	1999-10-11	1999-10-11	Pharmaceutically active compounds
GB0018656A GB0018656D0 (en)	2000-07-28	2000-07-28	Pharmaceutically active compounds

Publications (1)

Publication Number	Publication Date
MA26825A1 true MA26825A1 (fr)	2004-12-20

Family

ID=26244757

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26586A MA26825A1 (fr)	1999-10-11	2002-04-05	Derives de pyrazolo [4,3-d] pyrimidine

Country Status (49)

Country	Link
US (4)	US6677335B1 (fr)
EP (1)	EP1220856B1 (fr)
JP (1)	JP3834236B2 (fr)
KR (1)	KR100549152B1 (fr)
CN (3)	CN100378100C (fr)
AP (1)	AP1238A (fr)
AT (1)	ATE284404T1 (fr)
AU (1)	AU779065B2 (fr)
BG (1)	BG106678A (fr)
BR (1)	BR0014698A (fr)
CA (1)	CA2387357C (fr)
CO (1)	CO5251477A1 (fr)
CR (2)	CR6617A (fr)
CU (1)	CU23198A3 (fr)
CZ (1)	CZ20021158A3 (fr)
DE (1)	DE60016615T2 (fr)
DK (1)	DK1220856T3 (fr)
DZ (1)	DZ3220A1 (fr)
EA (1)	EA004982B1 (fr)
EE (1)	EE05181B1 (fr)
EG (1)	EG24411A (fr)
ES (1)	ES2232502T3 (fr)
GE (2)	GEP20033142B (fr)
GT (1)	GT200000171A (fr)
HK (3)	HK1050367A1 (fr)
HR (1)	HRP20020317B1 (fr)
HU (1)	HUP0203450A3 (fr)
IL (2)	IL149026A0 (fr)
IN (4)	IN2002MU00385A (fr)
IS (1)	IS2181B (fr)
MA (1)	MA26825A1 (fr)
MX (1)	MX228340B (fr)
MY (1)	MY130319A (fr)
NO (1)	NO322856B1 (fr)
NZ (1)	NZ518078A (fr)
OA (1)	OA12061A (fr)
PA (1)	PA8504501A1 (fr)
PE (1)	PE20010737A1 (fr)
PH (1)	PH12000002783B1 (fr)
PL (1)	PL357536A1 (fr)
PT (1)	PT1220856E (fr)
RS (1)	RS50476B (fr)
SI (1)	SI1220856T1 (fr)
SK (1)	SK4602002A3 (fr)
SV (1)	SV2002000195A (fr)
TN (1)	TNSN00199A1 (fr)
TR (1)	TR200200989T2 (fr)
TW (1)	TWI265925B (fr)
WO (1)	WO2001027113A2 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235625B2 (en)	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB0000561D0 (en) *	2000-01-11	2000-03-01	Pfizer Ltd	Treatment of diabetic ulcers
US6774128B2 (en) *	2000-04-19	2004-08-10	Johns Hopkins University	Methods for prevention and treatment of gastrointestinal disorders
US6271228B1 (en) *	2000-04-28	2001-08-07	Pfizer Inc.	Blood pressure stabilization during hemodialysis
EP1176142A1 (fr) *	2000-07-28	2002-01-30	Pfizer Inc.	Procédé pour la préparation de pyrazoles
US6420557B1 (en)	2000-07-28	2002-07-16	Pfizer Inc.	Crystalline therapeutic agent
US6407259B1 (en)	2000-07-28	2002-06-18	Pfizer Inc.	Process for the preparation of pyrazoles
EE200300045A (et) *	2000-07-28	2004-12-15	Pfizer Inc.	Kristalne ravimaine
GB0025782D0 (en) *	2000-10-20	2000-12-06	Pfizer Ltd	Use of inhibitors
US6548508B2 (en)	2000-10-20	2003-04-15	Pfizer, Inc.	Use of PDE V inhibitors for improved fecundity in mammals
FR2820319B3 (fr) *	2001-02-08	2003-12-05	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
DE10135815A1 (de) *	2001-07-23	2003-02-06	Bayer Ag	Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
MXPA04010951A (es) *	2002-05-23	2005-06-08	Pfizer	Nueva combinacion.
GB0214784D0 (en) *	2002-06-26	2002-08-07	Pfizer Ltd	Novel combination
DE10229778A1 (de) *	2002-07-03	2004-01-29	Bayer Ag	Neue Verwendung von Imidazotriazinonen
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US7323462B2 (en)	2002-12-10	2008-01-29	Pfizer Inc.	Morpholine dopamine agonists
ES2341240T3 (es)	2002-12-13	2010-06-17	Warner-Lambert Company Llc	Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
RS51768B (sr)	2003-02-27	2011-12-31	Palau Pharma S.A.	Derivati pirazolpiridina
WO2004096810A1 (fr)	2003-04-29	2004-11-11	Pfizer Limited	5,7-diaminopyrazolo`4,3-d!pyrimidines utiles pour le traitement de l'hypertension
BRPI0411347A (pt) *	2003-06-10	2006-07-11	Pfizer	combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
JP2006219373A (ja) *	2003-06-13	2006-08-24	Daiichi Asubio Pharma Co Ltd	Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DE10360835A1 (de) *	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
WO2005097799A1 (fr)	2004-04-07	2005-10-20	Pfizer Limited	Pyrazolo`4,3[4,3-d]pyrimidines
ATE412648T1 (de)	2005-03-21	2008-11-15	Pfizer Ltd	Substituierte triazolderivate als oxytocinantagonisten
US8227475B2 (en)	2005-05-12	2012-07-24	Pfizer Inc.	Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
ES2645371T3 (es)	2005-06-06	2017-12-05	Intra-Cellular Therapies, Inc.	Compuestos orgánicos
EP2258359A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
CA2625210A1 (fr)	2005-10-31	2007-05-10	Braincells, Inc.	Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
AR058119A1 (es) *	2005-12-20	2008-01-23	Pfizer Prod Inc	Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui)
US20080261995A1 (en) *	2005-12-21	2008-10-23	Pfizer Inc.	Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
UY30111A1 (es) *	2006-02-03	2007-04-30	Recordati Ireland Ltd	Sales de adicion de acido de n-(3-(4-(2-metoxifenil)-1-piperazinil)-propil)-7-oxo-5-trifluormetil-7h-tieno (3,2-b) piran-3-carboxamida
AU2007223036A1 (en) *	2006-03-08	2007-09-13	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2026813A2 (fr) *	2006-05-09	2009-02-25	Braincells, Inc.	Neurogenèse induite par le récepteur 5ht
EP2377531A2 (fr)	2006-05-09	2011-10-19	Braincells, Inc.	Neurogénèse par modulation de l'angiotensine
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
US9255099B2 (en)	2006-06-06	2016-02-09	Intra-Cellular Therapies, Inc.	Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
US20080051413A1 (en) *	2006-08-25	2008-02-28	Kaohsiung Medical University	Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
US7998971B2 (en) *	2006-09-08	2011-08-16	Braincells Inc.	Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (fr) *	2006-09-19	2009-06-10	Braincells, Inc.	Combinaison comprenant un agent ppar et un deuxième agent neurogène pour le traitement d'une maladie du système nerveux central, pour augmenter la différentiation neuronale et pour augmenter la neurogenèse
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20080081816A1 (en) *	2006-10-03	2008-04-03	Kaohsiung Medical University	Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
WO2008070095A1 (fr)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Nouvelles utilisations
KR20100094551A (ko)	2007-12-06	2010-08-26	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
US8664207B2 (en)	2008-12-06	2014-03-04	Intra-Cellular Therapies, Inc.	Organic compounds
SG171777A1 (en)	2008-12-06	2011-07-28	Intra Cellular Therapies Inc	Organic compounds
SG171776A1 (en)	2008-12-06	2011-07-28	Intra Cellular Therapies Inc	Organic compounds
BRPI0922809A2 (pt)	2008-12-06	2018-05-29	Intracellular Therapies Inc	compostos orgânicos
EP2367431B1 (fr)	2008-12-06	2015-08-05	Intra-Cellular Therapies, Inc.	Composés organiques
MX2011005933A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
EP2379076B1 (fr)	2008-12-23	2014-11-12	The Trustees of Columbia University in the City of New York	Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en)	2009-02-27	2009-04-08	Vantia Ltd	New compounds
US9468637B2 (en)	2009-05-13	2016-10-18	Intra-Cellular Therapies, Inc.	Organic compounds
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
EP2576551A4 (fr)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	Composés organiques
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
US10561656B2 (en)	2011-06-10	2020-02-18	Intra-Cellular Therapies, Inc.	Organic compounds
US9402877B2 (en)	2011-11-04	2016-08-02	Xion Pharmaceuticals Corporation	Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2804603A1 (fr)	2012-01-10	2014-11-26	President and Fellows of Harvard College	Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2013109738A1 (fr)	2012-01-17	2013-07-25	The Trustees Of Columbia University In The City Of New York	Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
AR091507A1 (es)	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9801882B2 (en)	2013-02-17	2017-10-31	Intra-Cellular Therapies, Inc.	Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
JP2016518343A (ja)	2013-03-15	2016-06-23	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
JP6437519B2 (ja)	2013-03-15	2018-12-12	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
CN112851683A (zh) *	2013-06-21	2021-05-28	细胞内治疗公司	游离碱晶体
US10899756B2 (en)	2013-07-17	2021-01-26	The Trustees Of Columbia University In The City Of New York	Phosphodiesterase inhibitors and uses thereof
AR102315A1 (es) *	2014-04-02	2017-02-22	Bayer Cropscience Ag	Derivados de pirazolil-nicotin(tio)amida sustituidos y su uso como fungicidas
JP6810613B2 (ja)	2014-06-20	2021-01-06	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	有機化合物
TWI686394B (zh)	2014-08-07	2020-03-01	美商內胞醫療公司	有機化合物
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
EP3725789B1 (fr)	2014-09-17	2022-03-09	Intra-Cellular Therapies, Inc.	Dérivés de 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one en tant qu'inhibiteurs de phosphodiestérase 1 (pde1) pour le traitement de maladies, troubles ou blessures du sytème nerveux central (snc)
WO2017172795A1 (fr)	2016-03-28	2017-10-05	Intra-Cellular Therapies, Inc.	Nouvelles compositions et méthodes
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
WO2018049214A1 (fr)	2016-09-09	2018-03-15	Incyte Corporation	Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
US20180072741A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyrimidine compounds and uses thereof
KR102507967B1 (ko)	2016-09-09	2023-03-09	인사이트 코포레이션	Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도
EP3509589B1 (fr)	2016-09-12	2021-11-17	Intra-Cellular Therapies, Inc.	Nouvelles utilisations
WO2018152220A1 (fr)	2017-02-15	2018-08-23	Incyte Corporation	Composés de pyrazolopyridine et leurs utilisations
US10722495B2 (en)	2017-09-08	2020-07-28	Incyte Corporation	Cyanoindazole compounds and uses thereof
US11839614B2 (en)	2018-01-31	2023-12-12	Intra-Cellular Therapies, Inc.	Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
US10752635B2 (en)	2018-02-20	2020-08-25	Incyte Corporation	Indazole compounds and uses thereof
MX2020008656A (es)	2018-02-20	2020-12-09	Incyte Corp	Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
JP7399968B2 (ja)	2018-09-25	2023-12-18	インサイト・コーポレイション	Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
CN114450276A (zh)	2019-08-06	2022-05-06	因赛特公司	Hpk1抑制剂的固体形式
CN113493459B (zh) *	2020-04-07	2022-12-13	广州白云山医药集团股份有限公司白云山制药总厂	Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2089971A (en)		1937-08-17		Condensation products of
DE425921C (de) *	1923-08-11	1926-02-27	Ernst Otto Baum	Pressluftzugmaschine fuer Bergwerke
US4871843A (en)	1983-10-18	1989-10-03	Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle	Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
FR2558263B1 (fr) *	1984-01-12	1986-04-25	Commissariat Energie Atomique	Accelerometre directif et son procede de fabrication par microlithographie
US4663326A (en)	1985-04-04	1987-05-05	Warner-Lambert Company	Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
GB8817651D0 (en)	1988-07-25	1988-09-01	Smith Kline French Lab	Chemical compounds
IL95975A (en)	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
GB9119704D0 (en)	1991-09-14	1991-10-30	Pfizer Ltd	Therapeutic agents
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
GB9202238D0 (en)	1992-02-03	1992-03-18	Wellcome Found	Compounds
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en)	1992-06-26	1998-03-31	Pfizer Inc	Purinone antianginal agents
GB9213623D0 (en)	1992-06-26	1992-08-12	Pfizer Ltd	Therapeutic agents
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
GB9315017D0 (en)	1993-07-20	1993-09-01	Glaxo Lab Sa	Chemical compounds
US5728705A (en)	1993-10-04	1998-03-17	The Trustees Of Columbia University In The City Of New York	Method of inducing vasorelaxation to treat pulmonary hypertension
GB9423911D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5656629A (en)	1995-03-10	1997-08-12	Sanofi Winthrop, Inc.	6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
HUP9801394A3 (en)	1995-03-10	2000-07-28	Sanofi Pharmaceuticals Inc New	6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
US5952006A (en)	1995-09-29	1999-09-14	L.A.M. Pharmaceuticals, Llc	Drug preparations for treating impotency
DE19540642A1 (de)	1995-11-01	1997-05-07	Stief Christian Georg Priv Doz	Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
GB9612514D0 (en)	1996-06-14	1996-08-14	Pfizer Ltd	Novel process
PL336586A1 (en)	1997-04-25	2000-07-03	Pfizer	Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
ATE333279T1 (de)	1997-05-19	2006-08-15	Zonagen Inc	Kombinationstherapie zur modulation der humanen sexualreaktion
CN1309561A (zh)	1997-05-29	2001-08-22	持田制药株式会社	***机能障碍治疗剂
EA200000526A1 (ru)	1997-12-16	2000-12-25	Пфайзер Продактс Инк.	Комбинация, эффективная для лечения импотенции
HUP0102543A3 (en)	1998-04-20	2002-01-28	Pfizer	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
WO1999059584A1 (fr)	1998-05-20	1999-11-25	Schering Corporation	Combinaison de phentolamine et d'inhibiteurs de la phosphodiesterase gmp cyclique utilises dans le traitement des dysfonctions sexuelles
US6087368A (en)	1998-06-08	2000-07-11	Bristol-Myers Squibb Company	Quinazolinone inhibitors of cGMP phosphodiesterase
EP1120120A4 (fr)	1998-10-05	2009-04-29	Eisai R&D Man Co Ltd	Comprimes se delitant immediatement dans la cavite buccale
JP2000119198A (ja)	1998-10-16	2000-04-25	Eisai Co Ltd	苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
CA2251255A1 (fr)	1998-10-20	2000-04-20	Mcgill University	L'utilisation d'agents dopaminergique dans le gestion de dysfonctionnement sexuel
IL132406A0 (en)	1998-10-21	2001-03-19	Pfizer Prod Inc	Treatment of bph with cgmp elevators
GB9823101D0 (en)	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
BR9915532A (pt)	1998-10-23	2001-08-14	Pfizer	Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual
GB9828340D0 (en)	1998-12-22	1999-02-17	Novartis Ag	Organic compounds
JP3199115B2 (ja) *	1998-12-24	2001-08-13	モトローラ株式会社	デジタル・アナログ変換回路
DE19903087A1 (de)	1999-01-27	2000-08-10	Forssmann Wolf Georg	Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
AU3724400A (en)	1999-03-08	2000-09-28	Merck & Co., Inc.	Methods and compositions for treating erectile dysfunction
IL137429A0 (en)	1999-07-28	2001-07-24	Pfizer Prod Inc	Methods and compsitions for treating diseases and conditions of the eye
WO2001008659A1 (fr)	1999-07-30	2001-02-08	Lakefield Minerals Ltd.	Preparations pharmaceutiques pour application directe destinees au traitement de la dyserection
AU779991B2 (en)	1999-08-10	2005-02-24	Board Of Regents, The University Of Texas System	Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
US6436944B1 (en)	1999-09-30	2002-08-20	Pfizer Inc.	Combination effective for the treatment of impotence
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
YU59100A (sh)	1999-10-11	2003-10-31	Pfizer Inc.	Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
US6407259B1 (en) *	2000-07-28	2002-06-18	Pfizer Inc.	Process for the preparation of pyrazoles
US6420557B1 (en) *	2000-07-28	2002-07-16	Pfizer Inc.	Crystalline therapeutic agent

2000
- 2000-09-14 TW TW089118861A patent/TWI265925B/zh not_active IP Right Cessation
- 2000-10-06 US US09/685,080 patent/US6677335B1/en not_active Expired - Fee Related
- 2000-10-09 PH PH12000002783A patent/PH12000002783B1/en unknown
- 2000-10-09 MY MYPI20004712A patent/MY130319A/en unknown
- 2000-10-09 EG EG20001281A patent/EG24411A/xx active
- 2000-10-10 PA PA20008504501A patent/PA8504501A1/es unknown
- 2000-10-10 TN TNTNSN00199A patent/TNSN00199A1/fr unknown
- 2000-10-10 GT GT200000171A patent/GT200000171A/es unknown
- 2000-10-11 ES ES00966347T patent/ES2232502T3/es not_active Expired - Lifetime
- 2000-10-11 IL IL14902600A patent/IL149026A0/xx unknown
- 2000-10-11 SK SK460-2002A patent/SK4602002A3/sk unknown
- 2000-10-11 DE DE60016615T patent/DE60016615T2/de not_active Expired - Lifetime
- 2000-10-11 DK DK00966347T patent/DK1220856T3/da active
- 2000-10-11 HU HU0203450A patent/HUP0203450A3/hu unknown
- 2000-10-11 CZ CZ20021158A patent/CZ20021158A3/cs unknown
- 2000-10-11 PT PT00966347T patent/PT1220856E/pt unknown
- 2000-10-11 CN CNB2005100625827A patent/CN100378100C/zh not_active Expired - Fee Related
- 2000-10-11 DZ DZ003220A patent/DZ3220A1/fr active
- 2000-10-11 GE GEAP20006408A patent/GEP20033142B/en unknown
- 2000-10-11 NZ NZ518078A patent/NZ518078A/en unknown
- 2000-10-11 PL PL00357536A patent/PL357536A1/xx not_active Application Discontinuation
- 2000-10-11 CN CNB008151954A patent/CN1204138C/zh not_active Expired - Fee Related
- 2000-10-11 GE GEAP20005578A patent/GEP20033068B/en unknown
- 2000-10-11 SV SV2000000195A patent/SV2002000195A/es unknown
- 2000-10-11 OA OA1200200104A patent/OA12061A/en unknown
- 2000-10-11 WO PCT/IB2000/001457 patent/WO2001027113A2/fr active Application Filing
- 2000-10-11 TR TR2002/00989T patent/TR200200989T2/xx unknown
- 2000-10-11 AU AU76784/00A patent/AU779065B2/en not_active Ceased
- 2000-10-11 KR KR1020027004643A patent/KR100549152B1/ko not_active IP Right Cessation
- 2000-10-11 SI SI200030593T patent/SI1220856T1/xx unknown
- 2000-10-11 RS YUP-314/02A patent/RS50476B/sr unknown
- 2000-10-11 EE EEP200200195A patent/EE05181B1/xx not_active IP Right Cessation
- 2000-10-11 AT AT00966347T patent/ATE284404T1/de not_active IP Right Cessation
- 2000-10-11 JP JP2001530331A patent/JP3834236B2/ja not_active Expired - Fee Related
- 2000-10-11 AP APAP/P/2002/002456A patent/AP1238A/en active
- 2000-10-11 PE PE2000001090A patent/PE20010737A1/es not_active Application Discontinuation
- 2000-10-11 BR BR0014698-6A patent/BR0014698A/pt not_active Application Discontinuation
- 2000-10-11 CO CO00077467A patent/CO5251477A1/es not_active Application Discontinuation
- 2000-10-11 EA EA200200337A patent/EA004982B1/ru not_active IP Right Cessation
- 2000-10-11 CN CNB2004100384099A patent/CN100383141C/zh not_active Expired - Fee Related
- 2000-10-11 EP EP00966347A patent/EP1220856B1/fr not_active Expired - Lifetime
- 2000-10-11 CA CA002387357A patent/CA2387357C/fr not_active Expired - Fee Related
2002
- 2002-03-21 IS IS6320A patent/IS2181B/is unknown
- 2002-03-21 CU CU20020060A patent/CU23198A3/es not_active IP Right Cessation
- 2002-03-28 IN IN385MU2002 patent/IN2002MU00385A/en unknown
- 2002-04-05 MA MA26586A patent/MA26825A1/fr unknown
- 2002-04-08 CR CR6617A patent/CR6617A/es not_active Application Discontinuation
- 2002-04-08 IL IL149026A patent/IL149026A/en not_active IP Right Cessation
- 2002-04-10 MX MXPA02003627 patent/MX228340B/es active IP Right Grant
- 2002-04-10 NO NO20021694A patent/NO322856B1/no not_active IP Right Cessation
- 2002-04-11 HR HR20020317A patent/HRP20020317B1/xx not_active IP Right Cessation
- 2002-05-09 BG BG106678A patent/BG106678A/bg unknown
2003
- 2003-04-10 HK HK03102607A patent/HK1050367A1/xx not_active IP Right Cessation
2004
- 2004-01-06 US US10/753,199 patent/US7176311B2/en not_active Expired - Fee Related
2005
- 2005-01-28 IN IN80MU2005 patent/IN2005MU00080A/en unknown
- 2005-03-11 HK HK05102106A patent/HK1069577A1/xx not_active IP Right Cessation
- 2005-11-18 HK HK05110418A patent/HK1078574A1/xx not_active IP Right Cessation
2006
- 2006-03-08 IN IN264MU2006 patent/IN2006MU00264A/en unknown
- 2006-08-11 US US11/463,931 patent/US20060293347A1/en not_active Abandoned
2007
- 2007-04-19 IN IN567MU2007 patent/IN2007MU00567A/en unknown
2008
- 2008-08-08 CR CR10191A patent/CR10191A/es not_active Application Discontinuation
2009
- 2009-05-20 US US12/469,311 patent/US20100035891A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MXPA02003627A (en)	2002-08-01
CN100378100C (zh)	2008-04-02
RS50476B (sr)	2010-03-02
TR200200989T2 (tr)	2002-09-23
HK1069577A1 (en)	2005-05-27
KR20020038942A (ko)	2002-05-24
WO2001027113A3 (fr)	2001-10-25
PA8504501A1 (es)	2003-06-30
MX228340B (en)	2005-06-07
CN1387531A (zh)	2002-12-25
EP1220856B1 (fr)	2004-12-08
US20040152712A1 (en)	2004-08-05
PL357536A1 (en)	2004-07-26
KR100549152B1 (ko)	2006-02-06
HUP0203450A2 (hu)	2003-01-28
GEP20033142B (en)	2003-12-25
HK1078574A1 (en)	2006-03-17
JP3834236B2 (ja)	2006-10-18
IS6320A (is)	2002-03-21
ATE284404T1 (de)	2004-12-15
US20100035891A1 (en)	2010-02-11
HUP0203450A3 (en)	2003-05-28
JP2003511453A (ja)	2003-03-25
IL149026A (en)	2010-05-17
IS2181B (is)	2006-12-15
CR10191A (es)	2008-10-10
EG24411A (en)	2009-05-25
CO5251477A1 (es)	2003-02-28
OA12061A (en)	2006-05-03
WO2001027113A2 (fr)	2001-04-19
NO20021694D0 (no)	2002-04-10
CN1204138C (zh)	2005-06-01
DZ3220A1 (fr)	2001-04-19
MY130319A (en)	2007-06-29
CN1680378A (zh)	2005-10-12
PE20010737A1 (es)	2001-07-19
AU7678400A (en)	2001-04-23
NO322856B1 (no)	2006-12-11
PH12000002783B1 (en)	2006-02-21
TNSN00199A1 (fr)	2002-05-30
AP2002002456A0 (en)	2002-06-30
NO20021694L (no)	2002-05-27
EE200200195A (et)	2003-08-15
EP1220856A2 (fr)	2002-07-10
SI1220856T1 (en)	2005-06-30
CN1572792A (zh)	2005-02-02
SK4602002A3 (en)	2003-04-01
GT200000171A (es)	2002-04-03
EA004982B1 (ru)	2004-10-28
CA2387357C (fr)	2007-10-02
BG106678A (bg)	2003-01-31
GEP20033068B (en)	2003-09-25
DK1220856T3 (da)	2005-03-14
US7176311B2 (en)	2007-02-13
DE60016615T2 (de)	2005-12-22
HRP20020317B1 (en)	2007-08-31
CZ20021158A3 (cs)	2003-03-12
US6677335B1 (en)	2004-01-13
SV2002000195A (es)	2002-07-16
IN2006MU00264A (fr)	2007-06-08
ES2232502T3 (es)	2005-06-01
CU23198A3 (es)	2007-03-23
IN2007MU00567A (fr)	2007-08-31
AP1238A (en)	2004-01-29
CN100383141C (zh)	2008-04-23
IL149026A0 (en)	2002-11-10
HK1050367A1 (en)	2003-06-20
NZ518078A (en)	2003-10-31
IN2002MU00385A (fr)	2005-08-26
DE60016615D1 (de)	2005-01-13
IN2005MU00080A (fr)	2006-05-19
BR0014698A (pt)	2002-06-18
EA200200337A1 (ru)	2002-10-31
HRP20020317A2 (en)	2004-04-30
EE05181B1 (et)	2009-06-15
CR6617A (es)	2004-02-23
YU31402A (sh)	2005-03-15
CA2387357A1 (fr)	2001-04-19
US20060293347A1 (en)	2006-12-28
PT1220856E (pt)	2005-02-28
TWI265925B (en)	2006-11-11
AU779065B2 (en)	2005-01-06

Publication	Publication Date	Title
MA26825A1 (fr)	2004-12-20	Derives de pyrazolo [4,3-d] pyrimidine
MA26851A1 (fr)	2004-12-20	Derives de pyrrolo [2,3-d] pyrimidine
DK1087971T3 (da)	2004-10-11	Pyrrolo[2,3-d]pyrimidinforbindelser
DE69915675D1 (de)	2004-04-22	Triazolo[4,5-d]pyrimidin-derivate
FR14C0019I2 (fr)	2015-01-02	COMPOSES DE PYRROLO 2,3d]PYRIMIDINE
DK1416935T3 (da)	2008-07-07	4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
DE69804273D1 (de)	2002-04-25	5h-Thiazolo[3,2-a]pyrimidinderivate
DE60103909D1 (de)	2004-07-22	2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE50001191D1 (de)	2003-03-06	Pyrazolo[4, 3-d]pyrimidine
NO20020931D0 (no)	2002-02-26	Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
NO995033D0 (no)	1999-10-15	6,7-disubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
NO995035D0 (no)	1999-10-15	5,6,7-trisubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
PT1326866E (pt)	2005-08-31	3,4-di-hidropirido[1,2-a]pirimidinas substituidas
ZA200202763B (en)	2003-06-25	Pyrazolo [4,3-D] pyrimidine derivatives.
DK1326866T3 (da)	2005-08-01	Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner